Status:
COMPLETED
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Renal Impairment
Eligibility:
All Genders
18-79 years
Phase:
PHASE1
Brief Summary
The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.
Eligibility Criteria
Inclusion
- good health other than renal impairment
- body mass index (BMI) between 18 and 40 kg/m2
Exclusion
- subject with renal impairment has not been on stable dose of concomitant medication for at least 2 weeks
- subject has liver enzyme abnormalities
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00750620
Start Date
September 1 2008
End Date
September 1 2009
Last Update
September 5 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim, California, United States, 92801
2
Miami, Florida, United States, 33014-3616